<DOC>
	<DOCNO>NCT01468350</DOCNO>
	<brief_summary>A double-blind , placebo-controlled , crossover study subject cerebral palsy ( CP ) evaluate safety tolerability effect dalfampridine extend release ( ER ) tablet sensorimotor function</brief_summary>
	<brief_title>Safety Tolerability Dalfampridine Subjects With Cerebral Palsy</brief_title>
	<detailed_description />
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Cerebral Palsy</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>A diagnosis CP No previous use dalfampridine formulation Ability perform require study procedure . Subjects capable fully extend flex hand Presence progressive neurological disease Severe CP define requirement use wheelchair time care taker constant assistance daily activity . This definition include spastic quadriplegia Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>